Aplexia Pharma Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
- Paid Up Capital ₹ 5.00 M
- Company Age 6 Year, 9 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth -2.46%
- Profit Growth 12.67%
- Ebitda 81.31%
- Net Worth -150.17%
- Total Assets -21.08%
About Aplexia Pharma
Aplexia Pharma Private Limited (APPL) is a Private Limited Foreign Company Incorporated In India incorporated in India on 15 May 2018 (Six years and nine months 11 days old ). Its registered office is in Champaran, Bihar, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 5.00 M, as per Ministry of Corporate Affairs (MCA) records.
Nita Mishra and Priyesh Pandey serve as directors at the Company.
Company Details
- Location
Champaran, Bihar, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U74999BR2018FTC038133
- Company No.
038133
- Company Classification
Private Limited Foreign Company Incorporated In India
- Incorporation Date
15 May 2018
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Patna
Industry
Who are the key members and board of directors at Aplexia Pharma?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Nita Mishra  | Director | 15-May-2018 | Current |
Priyesh Pandey  | Director | 15-May-2018 | Current |
Financial Performance of Aplexia Pharma.
Aplexia Pharma Private Limited, for the financial year ended 2022, experienced Minor drop in revenue, with a 2.46% decrease. The company also saw a substantial improvement in profitability, with a 12.67% increase in profit. The company's net worth observed a substantial decline by a decrease of 150.17%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Aplexia Pharma?
Unlock access to Aplexia Pharma's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Apleixa Technologies Private LimitedNita Mishra and Priyesh Pandey are mutual person
- Aplexia Sonic World Private Limited
Nita Mishra and Priyesh Pandey are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Aplexia Pharma?
Unlock and access historical data on people associated with Aplexia Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Aplexia Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Aplexia Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.